BlackRock (OLMA holder) discloses 6.24M Olema Pharmaceuticals shares in 13G/A

Rhea-AI Filing Summary

BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of common stock of Olema Pharmaceuticals, Inc. as of June 30, 2026. BlackRock reported beneficial ownership of 6,244,212 shares of Olema common stock, representing 7.1% of the outstanding class.

BlackRock reported sole voting power6,138,842 shares and sole dispositive power6,244,212 shares, with no shared voting or dispositive power. Various underlying clients and investors may have rights to dividends and sale proceeds, but no single person is reported to hold more than five percent of Olema’s outstanding common shares through these holdings.

Key Figures

Beneficial ownership: 6,244,212 shares Ownership percentage: 7.1% Sole voting power: 6,138,842 shares +2 more

5 metrics

Beneficial ownership 6,244,212 shares Common stock of Olema Pharmaceuticals beneficially owned by BlackRock as of June 30, 2026

Ownership percentage 7.1% Percent of Olema Pharmaceuticals common stock class reported owned by BlackRock

Sole voting power 6,138,842 shares Shares of Olema common stock over which BlackRock has sole power to vote

Sole dispositive power 6,244,212 shares Shares of Olema common stock over which BlackRock has sole power to dispose

Schedule 13G ownership threshold More than 5 percent Filing category triggered by BlackRock’s ownership in Olema common stock

Key Terms

beneficially owned, Sole Voting Power, dispositive power, parent holding company, +1 more

5 terms

beneficially owned financial

"reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 6,138,842.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole Dispositive Power 6,244,212.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

parent holding company financial

"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"

Schedule 13G regulatory

"In accordance with SEC Release No. 34-39538 this schedule reflects the securities beneficially owned"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 03:20 PM Accepted by SEC EDGAR 07/29/2026 - 03:19 PM Learn about SEC filing dates

FAQ

What percentage of Olema Pharmaceuticals (OLMA) does BlackRock currently report owning?

BlackRock reports beneficially owning 7.1% of Olema Pharmaceuticals’ common stock. This corresponds to 6,244,212 shares as of June 30, 2026, according to the amended Schedule 13G filing.

How many Olema Pharmaceuticals (OLMA) shares does BlackRock have voting power over?

BlackRock has sole voting power6,138,842 Olema Pharmaceuticals shares. It reports no shared voting power, meaning only these shares are subject to its voting discretion under the filing.

How many Olema Pharmaceuticals (OLMA) shares does BlackRock have dispositive power over?

BlackRock reports sole dispositive power6,244,212 Olema Pharmaceuticals shares. It indicates no shared dispositive power, so decisions to sell or otherwise dispose of these shares rest with BlackRock’s reporting business units.

Who actually benefits from BlackRock’s Olema Pharmaceuticals (OLMA) holdings?

The economic benefits are attributed to various persons, such as clients and fund investors. The filing states no single person’s interest in Olema’s common stock exceeds five percent of the total outstanding common shares.

What type of filing did BlackRock submit regarding Olema Pharmaceuticals (OLMA)?

BlackRock submitted an Amendment No. 1 to Schedule 13G for Olema Pharmaceuticals. This schedule reports passive beneficial ownership of more than five percent of a registered class of the company’s common stock.

Which BlackRock units are included in this Olema Pharmaceuticals (OLMA) ownership report?

The filing covers securities beneficially owned or deemed owned by specified Reporting Business Units of BlackRock and its subsidiaries. It excludes other BlackRock business units whose ownership is disaggregated under SEC Release No. 34-39538.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Olema Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

68062P106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 68062P106

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,138,842.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,244,212.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,244,212.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Olema Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 780 BRANNAN STREET SAN FRANCISCO CA 94103
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 68062P106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6244212
(b)	Percent of class: 7.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6138842
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6244212
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Olema Pharmaceuticals, Inc.. No one person's interest in the common stock of Olema Pharmaceuticals, Inc. is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/29/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7